| Objective:Observation and analysis of S-1 combined with Jianpi Pill on senile patients with colorectal cancer metastasis and their therapeutic effects on serum tumor markers(CEA,CA199,CA242),cyclooxygenase-2(COX-2),matrix metalloproteinase-2(MMP-2)on the level of expected shift of subsequent treatment of patients to provide a safe and reliable therapy combined with chemotherapy for the elderly to colorectal cancer.Methods:60 cases of patients with metastatic colorectal cancer in elderly patients from December 2012 to December2015 in our hospital anorectal wards,the average number of random distribution were divided into two groups,control group 30 patients were treated with S-1 as the center of the foundation treatment of the 30patients in the control group treatment group with Jianpi pill treatment(oral,9 grams each time,2 times/day),and the adverse reaction of RECIST and the"evaluation of patients with acute and subacute toxicity of anticancer drug WHO grading standards"treatment effect occurs,the automaticelectrochemiluminescenceinstrumenttodetectby immunoassay before and after treatment of serum CEA,CA199 and CA242 levels and with the method of ELISA by automatic enzyme immunoassay analyzer in serum COX-2 and MMP-2 levels before and after treatment were detected.Follow up method for self admission date to carry out follow-up by our department two statistical training of Coloproctology professionals(a deputy senior physician and a resident)by telephone and outpatient were recorded before and after treatment in patients with tumor markers(CEA,CA199,CA242),the incidence of detection the results of COX-2 and MMP-2 and the therapeutic effect,adverse reaction,the follow-up deadline of February 29,2016.Statistical analysis of the collected data packet by using SPSS20.0 software,count data with percentage(%),two groups were compared by chi square test;measurement data(standard deviation),were compared by t test,before and after the treatment group using paired t test,P<0.05,said there are significant differences.Results:the treatment group and the control group,the significant efficiency and benefit rate were(36.67%vs20.00%),(70.00%vs60.00%)(X~2=8.259,P<0.05;X~2=6.334,P<0.05).The two groups of patients before treatment the serum tumor markers CEA,CA199,CA242(t=2.335,close to the level of P>0.05;t=1.484,P>0.05;t=2.014,P>0.05);the patients in the treatment group after treatment serum tumor markers CEA,CA199,CA242 levels were significantly lower than those before treatment(t=13.527,P<0.05;t=14.264,P<0.05;t=11.025 P<0.05);patients in the control group after treatment,serum tumor markers CEA,CA199,CA242 level was lower than that before treatment(t=5.247,P<0.05;t=6.247,P<0.05;t=5.957,P<0.05);the patients in the treatment group after treatment serum tumor markers CEA,CA199,CA242 levels lower than the control group(t=8.521,t=9.247,P<0.05,P<0.05;t=8.214,P<0.05).Serum COX-2 before treatment in the two groups at the same level(t=2.013,P>0.05);the treatment group and the control group after treatment,serum COX-2 levels were higher than those before treatment(t=9.952,P<0.05;t=4.851,P<0.05);the patients in the treatment group after treatment,the serum levels of COX-2 were higher than that of the control group(t=8.226,P<0.05).Similar to the serum MMP-2 levels in patients with treatment of the two groups(t=1.556,P>0.05);the treatment group and the control group after treatment,serum MMP-2 levels were higher than those before treatment(t=12.524,P<0.05;t=9.624,P<0.05);the patients in the treatment group after treatment,the serum levels of MMP-2 were higher than that of the control group(t=6.223,P<0.05).The deadline to follow-up,the main adverse reactions in 60 cases of patients with myelosuppression and gastrointestinal adverse reactions,the treatment group and control group weremyelosuppression,incidenceofadversereactionswere gastrointestinal(16.67%vs46.67%),(26.67%vs53.33%)(2=6.749 P<0.05;X~2=7.865,P<0.05).Conclusion:Patients with metastasis has better clinical curative effect of S-1 combined with Jianpi pills in treatment of elderly patients with colorectal cancer,but also the optimization of serum tumor markers in patients(CEA,CA199,CA242,COX-2,MMP-2)level,clinical application should be considered. |
PDF Full Text Request